Effect of glibenclamide on extracellular potassium accumulation and the electrophysiological changes during myocardial ischaemia in the arterially perfused interventricular septum of rabbit

Cardiovascular Research
M N Hicks, S M Cobbe

Abstract

The aim was to study the effects of glibenclamide on the rate of rise of extracellular potassium concentration ([K+]o) and the electrophysiological changes that occur during myocardial ischaemia. The study was performed in isolated, arterially perfused interventricular septa from the rabbit. Six septa were treated with glibenclamide 10(-6) mol.litre-1 and there were six untreated controls (vehicle only). [K+]o and electrophysiological variables were compared before and during a 30 min period of global zero flow ischaemia. Prior to ischaemia, the extracellular potassium concentrations measured using potassium sensitive valinomycin electrodes were similar in the control and glibenclamide groups being 4.0 (SEM 0.1) and 4.0 (0.1) mmol.litre-1 respectively. [K+]o rose during ischaemia in both groups, and at 30 min was 13.3 (0.7) mmol.litre-1 in the control group. The increase in the glibenclamide group was less marked, reaching 9.2 (0.5) mmol.litre-1 (p less than 0.0005; unpaired t test). Glibenclamide had no electrophysiological effects prior to ischaemia. However, during ischaemia the decrease in action potential amplitude, action potential duration (APD), maximum upstroke velocity of the action potentials (dV/dtmax), and the exte...Continue Reading

Citations

Aug 1, 1993·Cardiovascular Drugs and Therapy·L H Opie
Jul 1, 1996·Diabetes Research and Clinical Practice·M Z Koltai
Jul 1, 1996·Diabetes Research and Clinical Practice·A Lomuscio, C Fiorentini
Jul 1, 1996·Diabetes Research and Clinical Practice·A Végh, J G Papp
Aug 26, 2000·European Journal of Pharmacology·W A CoetzeeM Avkiran
Aug 18, 2012·Antioxidants & Redox Signaling·Nitin T Aggarwal, Jonathan C Makielski
Aug 1, 1992·British Journal of Pharmacology·E Ruiz PetrichO F Schanne
Feb 26, 2013·American Journal of Physiology. Heart and Circulatory Physiology·Najate BenamerGregory E Morley
Jul 5, 2008·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Shiho T MoritaJiashin Wu
Aug 24, 2011·IEEE Transactions on Bio-medical Engineering·Kwanghyun SohnBonnie B Punske
Nov 26, 1993·The American Journal of Cardiology·B R LucchesiA C Uprichard
Dec 16, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Tomoaki SaitoHaruaki Nakaya
Jun 5, 1998·Clinical and Experimental Pharmacology & Physiology·D A Saint, Y Tang
Dec 15, 2015·Physiological Reviews·Monique N Foster, William A Coetzee
Jul 31, 1998·The American Journal of Physiology·H W BethellA A Grace

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.